EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia

James Bussel, Barbara Stegmann, Pamela Baker, Abbie Oey, Yanxin Jiang, Rebecca Zaha, Hillary Van Valkenburgh, Babajide Keshinro

American Journal of Perinatology · 01.07.2026 · 43 (10) · 1335-1344

DOI: 10.1055/a-2753-9323 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift American Journal of Perinatology, erschienen am 01.07.2026. Verfasst von James Bussel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medical College, New York, New York, United States. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunoglobulins, Intravenous, Prednisone, Thrombocytopenia, Neonatal Alloimmune. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study is sponsored by Johnson & Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nipocalimab, a neonatal Fc receptor blocker, showed evidence of efficacy and safety in preventing or delaying fetal anemia in a phase 2 study of early-onset severe hemolytic disease of the fetus and newborn, demonstrating potential for treatment of other maternal immunoglobulin G alloantibody-mediated fetal diseases. The phase 3 FREESIA-3 study aims to evaluate the efficacy and safety of nipocalimab or intravenous immunoglobulin (IVIG) with prednisone in pregnancies with a previous occurrence of fetal and neonatal alloimmune thrombocytopenia (FNAIT) with or without intracranial hemorrhage or severe fetal/neonatal bleeding (high- or standard-risk, respectively). FREESIA-3 is a phase 3, open-label, randomized, multicenter study in pregnant individuals at risk for FNAIT. Participants are randomized 4:1 to receive either weekly 45 mg/kg intravenous nipocalimab or weekly IVIG with prednisone starting at 13 to 18 weeks of gestational age (standard-risk) or 12 weeks of gestational age (high-risk) until delivery. During treatment, pregnant participants will receive ultrasound monitoring every 2 weeks for fetal bleeding, growth, and development. Postnatal follow-up is 24 weeks for maternal participants and 104 weeks for neonates/infants. The primary endpoint is an adverse outcome of death or adjudicated severe bleeding in utero up to 1 week postbirth, or platelet count at birth of < 30 × 109/L in a fetus/neonate. Secondary endpoints include fetal/neonatal death, neonatal platelet count at birth, nadir neonatal platelet count over 1 week postbirth, neonate requiring platelet transfusion(s), adjudicated fetal and neonatal bleeding up to 1 week postbirth, neonate receiving IVIG for thrombocytopenia, safety in maternal participants and neonates/infants, and immunogenicity of nipocalimab. Exploratory endpoints include patient- and caregiver-reported outcome assessments and nipocalimab pharmacokinetics and pharmacodynamics. FREESIA-3, an open-label, multicenter, randomized, phase 3 study, will evaluate the efficacy and safety of nipocalimab in both standard- and high-risk pregnancies for FNAIT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmunoglobulins, IntravenousPrednisoneThrombocytopenia, Neonatal AlloimmuneFemaleHumansInfant, NewbornPregnancyGestational Age

Substanzen

Antibodies, Monoclonal, HumanizedImmunoglobulins, IntravenousnipocalimabPrednisone

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medical College, New York, New York, United States.
  • New York Presbyterian Hospital, New York, New York, United States.
  • Johnson & Johnson, Spring House, Pennsylvania, United States.
  • Johnson & Johnson Biologics BV, Leiden, the Netherlands.

Förderung

  • This study is sponsored by Johnson & Johnson

Zitieren

APA

Bussel, J., Stegmann, B., Baker, P., Oey, A., Jiang, Y., Zaha, R., Van Valkenburgh, H., & Keshinro, B. (2026). Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia. American Journal of Perinatology, 43(10), 1335-1344. https://doi.org/10.1055/a-2753-9323

Vancouver

Bussel J, Stegmann B, Baker P, Oey A, Jiang Y, Zaha R, et al. Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia. American Journal of Perinatology. 2026;43(10):1335-1344. doi:10.1055/a-2753-9323

BibTeX
@article{Bussel2026,
  author = {Bussel, James and Stegmann, Barbara and Baker, Pamela and Oey, Abbie and Jiang, Yanxin and Zaha, Rebecca and Van Valkenburgh, Hillary and Keshinro, Babajide},
  title = {Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia},
  journal = {American Journal of Perinatology},
  year = {2026},
  volume = {43},
  number = {10},
  pages = {1335--1344},
  doi = {10.1055/a-2753-9323}
}
Kostenlos starten →